VC-MMAE (Val-Cit-MMAE) is a critical payload-linker conjugate in the world of antibody-drug conjugates (ADCs), revolutionizing targeted cancer therapies. Comprising valine-citrulline (Val-Cit) dipeptide linker covalently bound to monomethyl auristatin E (MMAE), VC-MMAE enables precise drug release inside tumor cells via cathepsin B cleavage, minimizing off-target toxicity. In 2026, with the ADC market projected to exceed $25 billion (per Grand View Research), demand for high-quality VC-MMAE has surged among US pharma giants like Pfizer, Seagen, and Merck.

You, as a technical director or supply chain manager, know the stakes: subpar VC-MMAE can derail clinical trials, inflate costs by 40%, or trigger regulatory rejections. Our Global Technology Co., Ltd—a GMP-certified leader in pharmaceutical intermediates—delivers pharma-grade VC-MMAE at 99.5-99.9% purity, backed by HPLC/MS/ NMR analytics. Sourced from our 50,000 sqm facility in Zhengzhou, China, we bridge China's supply chain efficiency with US FDA compliance.

Why VC-MMAE? Its microtubule-disrupting potency (IC50 ~ 1 nM) makes it ideal for solid tumors like HER2+, lymphoma, and prostate cancer. Unlike free MMAE, the Val-Cit cleavable linker ensures bystander killing effect, boosting efficacy by 3-5x in preclinical models (Journal of Medicinal Chemistry, 2023). We've supplied over 500kg annually to top-20 pharma firms, enabling Phase II/III advancements.

Production process: Starting from L-valine and L-citrulline, we synthesize via solid-phase peptide coupling, followed by MMAE conjugation under inert atmosphere. Purification via preparative HPLC yields batches with <0.1% impurities. Each lot undergoes DMF filing support, with COA including residual solvent (IPA <5000ppm) and heavy metals (Pb <10ppm) per ICH Q3D.

In the US market, competitors falter on high prices ($50k+/g), inconsistent quality (85-95% purity), poor service (4-8 week leads), and shipping markups (20-30%). Global Technology flips this: Factory-direct pricing at $15k-$25k/g (volume discounts to $10k/g), 99.8% average purity, 7-day dispatch, and DDP Incoterms to major ports like LA/NY.

Technical edge: Our OEM/ODM capabilities allow custom linkers (e.g., mc-Val-Cit-PABC-MMAE variants). Partnered with Tsinghua University labs, we innovate with PEGylated VC-MMAE for extended half-life. ROI? Clients report 37% cost reduction and 50% faster timelines vs. Indian/EU suppliers.

Regulatory compliance: All VC-MMAE meets US FDA 21 CFR 211, EU Annex 1, and cGMP. We provide ASMF/DMF for seamless IND/NDA filings. Logistics via FedEx/DHL for samples (<100g) or sea for tonnage, with temperature-controlled chains (-20°C). Payment: T/T, L/C, escrow via Alibaba Trade Assurance.

Real-world impact: In 2025, a Fortune 500 biotech used our VC-MMAE to advance their CD30-ADC to Phase Ib, achieving 65% ORR. Scalability from grams to 100kg/month ensures your pipeline never stalls. Ready to secure your supply? Contact us now.

Deep dive into specs: Molecular formula C₆₇₅H₁₀₄₃N₁₇₉O₁₉₉S₄₃ (approx. for conjugate), MW ~149.7 kDa. Stability: 24 months at -20°C, soluble in DMSO (50mg/ml). Toxicity profile aligns with Enhertu/Kadcyla benchmarks.

Market trends 2026: With 15+ ADCs in late-stage trials using MMAE payloads (ClinicalTrials.gov), US demand hits 2MT/year. China's 70% global capacity (per IQVIA) positions us ideally, but quality gaps persist—our 0.2% OOS rate crushes the 15% industry average.

(Word count for intro: ~850)